 Low-dose zidovudine children human immunodeficiency virus type infection perinatal period report one-year results noncomparative study safety tolerance low-dose zidovudine azidothymidine human immunodeficiency virus type infants children baseline mean age years symptomatic Disease Control classification patients zidovudine months full year therapy mean duration follow-up days range days initial therapy daily doses day equivalent mg/kg day treatment neutropenia anemia Twenty-nine children initial therapy entire study Zidovudine dosage times children due time full-dose therapy total duration protocol patients Children mild symptoms study entry likely full-dose therapy children severe symptoms time full-dose therapy duration protocol former group latter clinical adverse experiences Thirty-seven children trimethoprim-sulfametoxazole prophylaxis Pneumocystis carinii pneumonia